Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152328 | 0.86 | NOTUM (0.72) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL3891046 | 0.78 | NOTUM (0.60) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL5168614 | 0.78 | NOTUM (0.60) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL29556202 | 0.78 | MAPT (0.61) | NOTUMLMNATP53SMN1; SMN2NPC1 | |
| SCHEMBL1960697 | 0.78 | MAPT (0.61) | NOTUMLMNATP53SMN1; SMN2NPC1 | |
| SCHEMBL10627585 | 0.78 | NOTUM (0.60) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL3819681 | 0.78 | NOTUM (0.61) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL21150838 | 0.78 | NOTUM (0.63) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL4581917 | 0.78 | NOTUM (0.60) | NOTUMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL3369534 | 0.78 | NOTUM (0.60) | NOTUMLMNATP53SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105283452-B | Tetrazolone derivatives | 豪夫迈·罗氏有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-1809620-B1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20070299110-A1 | Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate | ADDEX PHARMACEUTICALS SA (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1809620-A1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048771-A1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299110-A1 | Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate | GRM5, GRIK5, GRM1 | NOTUM 2925/4885KEAP1 3138/4885LMNA 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.